02:00 PM EDT, 07/23/2025 (MT Newswires) -- Abivax ( ABVX ) shares catapulted 555% amid heavy trading after the company said late Tuesday its investigational ulcerative colitis drug candidate obefazimod met the primary endpoint of clinical remission in two global phase 3 trials.

More than 23.3 million shares traded intraday compared with a daily average of roughly 346,000.

Anebulo Pharmaceuticals ( ANEB ) said Wednesday that its board and a special committee of independent directors recommended a reverse stock split at a ratio of not less than 1-for-2,500 and not greater than 1-for-7,500 as part of its going-private transactions.

The split and reduction in the number of shareholders will enable Anebulo to terminate its registration as a US Securities and Exchange Commission reporting company, it said.

Shares soared 75% as intraday trading volume increased to over 18.2 million from a daily average of about 15,000.

Clearside Biomedical ( CLSD ) said Wednesday that Health Canada approved Xipere for suprachoroidal use in the treatment of uveitic macular edema.

Xipere has also been approved for use in the US, Australia, and Singapore, and is under regulatory review in China, the biopharmaceutical company said.

Shares surged 61% as intraday trading volume climbed to more than 211.1 million from a daily average of about 470,000.

Price: 65.51, Change: +55.51, Percent Change: +555.10